MX2022014886A - Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. - Google Patents
Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.Info
- Publication number
- MX2022014886A MX2022014886A MX2022014886A MX2022014886A MX2022014886A MX 2022014886 A MX2022014886 A MX 2022014886A MX 2022014886 A MX2022014886 A MX 2022014886A MX 2022014886 A MX2022014886 A MX 2022014886A MX 2022014886 A MX2022014886 A MX 2022014886A
- Authority
- MX
- Mexico
- Prior art keywords
- tucatinib
- oxaliplatin
- trastuzumab
- positive cancer
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032223P | 2020-05-29 | 2020-05-29 | |
| PCT/US2021/034715 WO2021243123A1 (en) | 2020-05-29 | 2021-05-28 | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014886A true MX2022014886A (es) | 2023-01-04 |
Family
ID=76601765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014886A MX2022014886A (es) | 2020-05-29 | 2021-05-28 | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230173067A1 (https=) |
| EP (1) | EP4157257A1 (https=) |
| JP (1) | JP2023527794A (https=) |
| KR (1) | KR20230027068A (https=) |
| CN (1) | CN115768416A (https=) |
| AU (1) | AU2021281336A1 (https=) |
| CA (1) | CA3183592A1 (https=) |
| IL (1) | IL298538A (https=) |
| MX (1) | MX2022014886A (https=) |
| WO (1) | WO2021243123A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120091828A (zh) * | 2022-10-12 | 2025-06-03 | 中外制药株式会社 | 含有肽、表面活性剂和聚合物的组合物 |
| WO2024130003A1 (en) * | 2022-12-15 | 2024-06-20 | Bolt Biotherapeutics, Inc. | Cancer combination treatment method |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2012323890A1 (en) | 2011-10-14 | 2014-05-29 | Array Biopharma Inc. | Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| EP3344251B1 (en) * | 2015-09-04 | 2021-04-28 | Aslan Pharmaceuticals PTE Limited | A combination therapy comprising varlitinib and an anticancer agent |
| PT3589661T (pt) * | 2017-03-02 | 2024-01-29 | Genentech Inc | Tratamento com adjuvante de cancro da mama positivo para her2 |
| BR112019022280A2 (pt) * | 2017-04-28 | 2020-05-19 | Seattle Genetics Inc | tratamento de cânceres de her2 positivo |
| EP3727368A4 (en) * | 2017-12-19 | 2021-10-20 | Abraxis BioScience, LLC | METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY |
-
2021
- 2021-05-28 MX MX2022014886A patent/MX2022014886A/es unknown
- 2021-05-28 US US17/926,206 patent/US20230173067A1/en active Pending
- 2021-05-28 AU AU2021281336A patent/AU2021281336A1/en not_active Abandoned
- 2021-05-28 IL IL298538A patent/IL298538A/en unknown
- 2021-05-28 KR KR1020227044996A patent/KR20230027068A/ko active Pending
- 2021-05-28 EP EP21734645.1A patent/EP4157257A1/en active Pending
- 2021-05-28 JP JP2022572329A patent/JP2023527794A/ja active Pending
- 2021-05-28 WO PCT/US2021/034715 patent/WO2021243123A1/en not_active Ceased
- 2021-05-28 CN CN202180038814.2A patent/CN115768416A/zh active Pending
- 2021-05-28 CA CA3183592A patent/CA3183592A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL298538A (en) | 2023-01-01 |
| US20230173067A1 (en) | 2023-06-08 |
| AU2021281336A1 (en) | 2022-12-15 |
| KR20230027068A (ko) | 2023-02-27 |
| WO2021243123A1 (en) | 2021-12-02 |
| CA3183592A1 (en) | 2021-12-02 |
| CN115768416A (zh) | 2023-03-07 |
| EP4157257A1 (en) | 2023-04-05 |
| JP2023527794A (ja) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013525A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t | |
| MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
| MX2020011653A (es) | Métodos de tratamiento para el abuso de sustancias. | |
| MX2022005903A (es) | Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2023001233A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. | |
| MX2023006793A (es) | Tratamientos conjuntos para tratamiento de cancer her2. | |
| WO2022031642A3 (en) | Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| MX2020001727A (es) | Terapia de combinacion. | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
| MX2023012766A (es) | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. | |
| MX2022004699A (es) | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| WO2021011844A3 (en) | Combination cancer therapy agents and methods | |
| WO2020005869A3 (en) | Compositions and methods for the treatment of cancer characterized with pcsk9 expression | |
| MX2021001764A (es) | Terapia de combinacion. | |
| MX2025006565A (es) | Terapia contra el cancer con capivasertib y fulvestrant | |
| PH12022553029A1 (en) | Treatments of prostate cancer with combinations of abiraterone acetate and niraparib | |
| MX2024005084A (es) | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. | |
| MX2023006983A (es) | Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr). |